Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2005-000171-18-FI (EUCTR)	12/05/2005	18/04/2005	A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3066A2-210-WW - N/A	A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3066A2-210-WW - N/A	Multiple Sclerosis (Relapsing-remitting MS and Secondary progressive MS with relapses)	Product Name: Temsirolimus Tablets Product Code: CCI-779 INN or Proposed INN: Temsirolimus Other descriptive name: WAY-130799	Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development	NULL	Not Recruiting			Female: yes Male: yes	180		Finland
2	NCT00228397 (ClinicalTrials.gov)	November 2003	16/9/2005	Study Evaluating CCI-779 in Relapsing Multiple Sclerosis	A Multicenter, Randomized, Double-blind, Long-term Extension Study to Determine the Safety, Tolerability, and Preliminary Efficacy of CCI-779 in Subjects With Relapsing Multiple Sclerosis.	Multiple Sclerosis, Relapsing-Remitting	Drug: CCI-779	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	N/A	N/A	Both	221	Phase 2	NULL